Overview

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is a research study that will investigate the effects of proton pump inhibitors (often used to treat stomach upset) on Gleevec® (a drug that is FDA-approved to treat some types of cancer) in healthy volunteers. Twelve healthy volunteers (six men and six women) will be recruited to complete the study. This research study will compare Gleevec® in the body when taken with and without proton pump inhibitors (PPI). Each volunteer will receive a 400 mg pill of Gleevec® on two occasions. On one occasion they will take the dose of Gleevec® alone (without PPI). On another occasion, they will take the Gleevec® after taking 40 mg of PPI daily by mouth for six days. Several blood samples will be drawn to measure the concentrations of Gleevec® and its breakdown products in the blood, with and without the influence of PPI.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
Novartis
Treatments:
Imatinib Mesylate
Omeprazole
Proton Pump Inhibitors